Navigation Links
PTC Therapeutics Announces Data from Additional Clinical Studies of PTC124 in Cystic Fibrosis Confirming Activity
Date:6/12/2008

inical benefit of PTC124 in adults and children with nonsense-mutation-mediated CF."

About Cystic Fibrosis

Cystic fibrosis (CF) is among the most common life-threatening genetic disorders worldwide. According to the Cystic Fibrosis Foundation, CF affects approximately 30,000 adults and children in the United States and, according to the European Cystic Fibrosis Foundation, it affects a similar number of patients in Europe. There is a commercially available genetic test to determine if a patient's CF is caused by a nonsense mutation, and it is estimated that nonsense mutations are the cause of CF in approximately 10% of patients in the United States. There is currently no available therapy to correct defective CFTR production and function. Instead, available treatments for CF are designed to alleviate the symptoms of the disease. These treatments include chest physical therapy to clear the thick mucus from the lungs, antibiotics to treat lung infections and a mucus-thinning drug designed to reduce the number of lung infections and improve lung function. In addition, the majority of cystic fibrosis patients take pancreatic enzyme supplements to assist with food absorption in digestion. There is a significant unmet medical need for treatments that address the underlying cause of CF. More information regarding CF is available through the Cystic Fibrosis Foundation (http://www.cff.org).

About PTC124

PTC124 is an orally delivered investigational new drug for the treatment of genetic disorders due to nonsense mutations. Nonsense mutations are single-point alterations in the genetic code that prematurely stop the translation process, preventing production of a functional protein. In Phase 2a clinical trials in nonsense-mutation-mediated cystic fibrosis (CF) and in nonsense-mutation-mediated Duchenne muscular dystrophy (DMD), PTC124 has demonstrated the ability to produce functional protein across a v
'/>"/>

SOURCE PTC Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)...  The Healthcare Analytics Summit 2014 (HAS ... Salt Lake City , Sept. 24-25 has added ... organizations in the U.S. and beyond.  HAS ,14, powered ... devoted to providing immersive learning experiences on the ... accountable care initiatives and population health managemen t ...
(Date:7/29/2014)... MOUNTAIN VIEW, Calif. , July 29, 2014 ... antivirals has amplified with rising incidence rates and ... absence of a preventative vaccine. Change is underway ... and interferon regimens towards highly effective, easily-tolerated, interferon-free ... http://photos.prnewswire.com/prnh/20140728/130662 Gilead,s mega blockbuster ...
(Date:7/29/2014)... LONDON , July 29, 2014 ... 2014 Global Frost & Sullivan Best Practices Award ... solution is a cloud-based platform that connects digital ... - such as providers, pharmaceutical companies, prevention and ... electronics. Each year, Frost & ...
Breaking Medicine Technology:Health Catalyst Adds Keynote Speakers, New Sessions, and Expands Attendee Limit for Healthcare Analytics Summit 2014 2Health Catalyst Adds Keynote Speakers, New Sessions, and Expands Attendee Limit for Healthcare Analytics Summit 2014 3Health Catalyst Adds Keynote Speakers, New Sessions, and Expands Attendee Limit for Healthcare Analytics Summit 2014 4Health Catalyst Adds Keynote Speakers, New Sessions, and Expands Attendee Limit for Healthcare Analytics Summit 2014 5A Treatment Revolution is Underway: All-Oral Therapies Transform Global Hepatitis C Antiviral Market 2A Treatment Revolution is Underway: All-Oral Therapies Transform Global Hepatitis C Antiviral Market 3A Treatment Revolution is Underway: All-Oral Therapies Transform Global Hepatitis C Antiviral Market 4Frost & Sullivan Commends Validic for Delivering Superior Customer Value through its mHealth Interoperability Technology Platform 2Frost & Sullivan Commends Validic for Delivering Superior Customer Value through its mHealth Interoperability Technology Platform 3Frost & Sullivan Commends Validic for Delivering Superior Customer Value through its mHealth Interoperability Technology Platform 4
... ZURICH , July 19, 2010 Today, Novo Nordisk ... designed to investigate the effects of modern insulins in,the management of type 2 diabetes.[1] ... Spanning 28 countries across ... largest observational study,in insulin therapy. , , ...
... July 16 Human erythropoietin (EPO) is a ... and spinal cord injury, and Parkinson,s disease. However, EPO drug ... cross the blood-brain barrier (BBB). In acute stroke or brain ... the insult when neuroprotection is still possible. Therefore, large molecule ...
Cached Medicine Technology:World's Largest Study on Insulin Therapy Completes Recruitment With 60,000 Patients 2World's Largest Study on Insulin Therapy Completes Recruitment With 60,000 Patients 3ArmaGen® Re-engineers Erythropoietin for Brain Penetration 2
(Date:7/29/2014)... rates rise in association with extremely hot weather. The ... 2003, for example, resulted in about 22,000 extra deaths. ... at the Institute of Epidemiology II at the Helmholtz ... the number of deaths caused by cardiovascular disease in ... temperatures in the study. , "Our findings confirm the ...
(Date:7/29/2014)... handle stressful situations better than others, and it,s ... show differences in how they respond. , Researchers ... brains of genetically identical mice that predicts how ... , The findings, published July 29 in ... prevent potential consequences of chronic stress -- such ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 Foot Levelers ... lecturer at the Florida Chiropractic Association (FCA) National Convention ... Effects on the Kinetic Chain Changes on Thursday, August ... talk is focusing on the positive impact functional foot ... such as low back pain, plantar fasciitis, and hammertoes. ...
(Date:7/29/2014)... Dallas, Texas (PRWEB) July 29, 2014 ... the Global Biosimilars Market report is an essential ... biosimilars industry. Using detailed company data, financial analysis, ... in-depth analysis of the current and future growth ... the various regulatory frameworks under which biosimilars are ...
(Date:7/29/2014)... Catalent Pharma Solutions, the global leader ... for pharmaceutical, biologic, and consumer health products, today ... US Platform Leader of Pharmaceutical Softgels, will present ... Formulations using Soft Capsule Delivery Systems” at the ... of Drug Delivery Systems (30-31 July 2014, Tokyo, ...
Breaking Medicine News(10 mins):Health News:Mortality rates increase due to extreme heat and cold 2Health News:A new brain-based marker of stress susceptibility 2Health News:Foot Levelers CEO Kent Greenawalt Speaking at FCA Convention 2Health News:World Biosimilars Market Value Exceed $262 Billion by 2019 Says a New Report Available at MarketOptimizer.org 2Health News:World Biosimilars Market Value Exceed $262 Billion by 2019 Says a New Report Available at MarketOptimizer.org 3Health News:World Biosimilars Market Value Exceed $262 Billion by 2019 Says a New Report Available at MarketOptimizer.org 4Health News:Catalent Expert to Present on Enhancing Bioavailability of Poorly Absorbed Drugs at Japan Society of Drug Delivery Systems 2
... of Oaks Development,Group announced today the company closed on ... 3603 Paesanos Parkway in north central,San Antonio. The ... 1604 and,Northwest Military Highway, will feature the company,s unique ... tenants, equity,investors and the developer. , ...
... and John Centrello decided to bank their baby,s cord blood with M.A.Z.E. ... hoping never to use it, but wanted to have it just in ... ... While pregnant, Danielle and John Centrello decided to bank their baby,s ...
... December 8, 2008Medical specialists at the nation,s largest professional ... have about data presented by the FDA in support ... and the potential effect of the federal agency,s analyses ... are to be conducted in the future. , It ...
... Unilens Vision Inc.,(OTC Bulletin Board: UVICF; TSX Venture ... specialty contact lenses,today announced the acquisition of the ... Inc. located in Michigan. , ... agreement, Unilens acquired certain assets of Aero,Contact Lens, ...
... chronic hepatitis C and advanced liver disease with long-term ... and liver inflammation, but the treatment did not slow ... study finds. , These findings come from the clinical ... and are reported in the Dec. 4 issue of ...
... Cancer Report Released by IARC; U.S. Groups List Six Critical Steps ... , ATLANTA, Dec. 9 Despite ... men and women in the United States continue to decline, cancer ... the year 2010, and low- and middle-income countries will feel the ...
Cached Medicine News:Health News:Oaks Development Group Closes on Third San Antonio Project 2Health News:Oaks Development Group Closes on Third San Antonio Project 3Health News:Local Child Treated In Clinical Trial To Ease Symptoms of Cerebral Palsy 2Health News:Local Child Treated In Clinical Trial To Ease Symptoms of Cerebral Palsy 3Health News:Local Child Treated In Clinical Trial To Ease Symptoms of Cerebral Palsy 4Health News:Unilens Vision Acquires Aero Contact Lens, Inc. 2Health News:Hepatitis C treatment reduces the virus but liver damage continues 2Health News:Hepatitis C treatment reduces the virus but liver damage continues 3Health News:Leading U.S. Cancer Organizations Unite Against the Growing Global Cancer Burden 2Health News:Leading U.S. Cancer Organizations Unite Against the Growing Global Cancer Burden 3Health News:Leading U.S. Cancer Organizations Unite Against the Growing Global Cancer Burden 4Health News:Leading U.S. Cancer Organizations Unite Against the Growing Global Cancer Burden 5Health News:Leading U.S. Cancer Organizations Unite Against the Growing Global Cancer Burden 6
... The new Guidant VASOVIEW® ... to deliver a new level ... harvesting for both the saphenous ... simultaneous cut-and-seal capability, it lets ...
...
... Now rapid intrapartum or antepartum GBS results ... versus 2 days. This revolutionary in vitro diagnostic ... designed to be run in the clinical lab ... and delivery nurses 24 hours a day, ...
... contains primers and a FAM-labeled probe that is ... the mecA gene. In addition, this ASR contains ... an internal control sequence. This ASR requires an ... reporter dyes such as the Cepheid SmartCycler System. ...
Medicine Products: